• Home
  • About Us
    Our Approach Our Team Board
  • Pipeline
  • News
  • Honor
  • Careers
  • Collaboration
  • Investor Relations
    Disclosure Contact IR
  • Contact
中文 ENG
    • Home
    • About us
      • Our Approach
      • Our Team
      • Board
    • Pipeline
    • News
    • Honor
    • Careers
    • Collaboration
    • Investor Relations
      • Disclosure
      • Contact IR
    • Contact
    • CN

COMPANY NEWS

Category Company News Enterprise Honor
2023 08

18

TYK Medicines Announces Enrollment of First Patient in Pivotal Phase II Trial of TY-9591 in Treatment of NSCLC with Brain Metastases

Discover More
2023 08

17

TYK Medicines Announced First Patient Dosed in Phase 1 clinical trial of its CDK7 inhibitor TY-2699a

Discover More
2023 07

04

TYK Medicine TY-4028 —The EGFR/HER2 tyrosine kinase inhibitor approved by CDE to conduct clinical trial

Discover More
2023 06

21

TYK Medicine TYK-00540—The first CDK2/4/6 inhibitor in China approved by FDA to conduct clinical trial

Discover More
2023 05

29

TYK Medicines and WuXi STA Launch Comprehensive Strategic Cooperation

Discover More
2023 05

17

TYK Medicine TY-2699a —The CDK7 inhibitorapproved by CDE to conduct clinical trial

Discover More
<12345>
CN ENG
  • Home
  • About Us
  • Pipeline
  • News
  • Honor
  • Careers
  • Investors
  • Contact
Powered by SE

Copyright © 2019 浙江同源康 版权所有 浙ICP备19008464号